+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Melatonin Inhibition of the in vivo Pituitary Response to Luteinizing Hormone-Releasing Hormone in the Neonatal Rat

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The effects of melatonin on the in vivo pituitary LH response to LH-releasing hormone (LHRH) were examined in neonatal male and female rats, in 35- to 44-day-old male rats, and in 35- to 44-day-old male animals which had been either pinealectomized or maintained in constant light for at least 3 weeks before use. Animals were given saline or melatonin (1–100 μg/rat) followed within 30 sec by saline or LHRH (10–1,000 ng/rat) at separate subcutaneous sites. Blood was collected following decapitation either without prior injection or 15, 30, 45, or 60 min afterwards. Serum LH concentrations were determined by double antibody radioimmunoassay. In neonatal male and female rats, melatonin (1 μg) significantly (p < 0.01) suppressed by approximately 65% serum LH at 15 min after LHRH. Suppression was maintained for at least 60 min, a finding which indicates that melatonin blocks rather than delays the response to LHRH. By contrast, in normal, pinealectomized, and constant light older male rats, melatonin (100 μg) had no detectable effect on either the magnitude or the time course of LH release by LHRH. These data extend our previous in vitro findings by demonstrating that melatonin is a potent inhibitor of the in vivo pituitary response to LHRH in neonatal rats but not in older animals. Neither pinealectomy nor constant light, both of which are assumed to reduce pineal melatonin production, for at least 3 weeks before use restores neonatal pituitary responsiveness to the pineal indole in the older animals.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 31
          : 1
          : 13-17
          Department of Pharmacology, Washington University Medical School, St. Louis, Mo., and Section on Neuroendocrinology, Laboratory of Developmental Neurobiology, NICHD, NIH, Bethesda, Md.
          123044 Neuroendocrinology 1980;31:13–17
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article